A retrospective study of 165 PC patients treated with FOLFIRINOX reported that prophylactic primary G-CSF usage reduced the risk of NP (55.6% to 31.6%; p = 0.003) and FN (18.5% to 1.8%; p = 0.002) and improved OS (8.8 to 14.7 months; HR: 1.766, p = 0.001) [49]. This evidence concerns the gene CSF3 and pachyonychia congenita.